CDK2 and cancer: As both low levels of BRCA1 and BRCA1 methylation are very common to BLBC38, and our data demonstrate elevated cyclin E1 in the BRCA1 methylated BLBC, a rational ongoing area of investigation is CDK2 inhibition to sensitize BRCA1 methylated or deficient cancers to PARP inhibitors.